<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Recommended antimicrobial therapy for specific pathogens causing community-acquired pneumonia in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Recommended antimicrobial therapy for specific pathogens causing community-acquired pneumonia in adults</h1>
<div class="graphic"><div class="figure"><div class="ttl">Recommended antimicrobial therapy for specific pathogens causing community-acquired pneumonia in adults</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1">Organism</td> <td class="subtitle1">Preferred <span style="white-space: nowrap;">antimicrobial(s)</span></td> <td class="subtitle1">Alternative <span style="white-space: nowrap;">antimicrobial(s)</span></td> </tr> <tr> <td colspan="3"><em>Streptococcus pneumoniae</em></td> </tr> <tr> <td class="indent1"> <ul> <li>Penicillin nonresistant; MIC &lt;2 mcg/mL*</li> </ul> </td> <td>Penicillin G, amoxicillin</td> <td>Macrolide, cephalosporins (oral [cefpodoxime, cefprozil, cefuroxime, cefdinir] or parenteral [cefuroxime, ceftriaxone, cefotaxime]), clindamycin, doxycycline, respiratory fluoroquinolone<sup>¶</sup></td> </tr> <tr> <td class="indent1"> <ul> <li>Penicillin resistant; MIC ≥2 mcg/mL*</li> </ul> </td> <td>Agents chosen on the basis of susceptibility, including cefotaxime, ceftriaxone, fluoroquinolone</td> <td>Vancomycin, linezolid, high-dose amoxicillin (3 g/day with penicillin MIC ≤4 mcg/mL)</td> </tr> <tr> <td colspan="3"><em>Haemophilus influenzae</em></td> </tr> <tr> <td class="indent1"> <ul> <li>Non-beta-lactamase producing</li> </ul> </td> <td>Amoxicillin</td> <td>Fluoroquinolone, doxycycline, azithromycin, clarithromycin<sup>Δ</sup></td> </tr> <tr> <td class="indent1"> <ul> <li>Beta-lactamase producing</li> </ul> </td> <td>Second- or third-generation cephalosporin, amoxicillin-clavulanate</td> <td>Fluoroquinolone, doxycycline, azithromycin, clarithromycin<sup>Δ</sup></td> </tr> <tr> <td><em>Mycoplasma pneumoniae/Chlamydophila pneumoniae</em></td> <td>Macrolide, a tetracycline</td> <td>Fluoroquinolone</td> </tr> <tr> <td><em>Legionella</em> species</td> <td>Fluoroquinolone, azithromycin</td> <td>Doxycycline</td> </tr> <tr> <td><em>Chlamydophila psittaci</em></td> <td>A tetracycline</td> <td>Macrolide</td> </tr> <tr> <td><em>Coxiella burnetii</em></td> <td>A tetracycline</td> <td>Macrolide</td> </tr> <tr> <td><em>Francisella tularensis</em></td> <td>Doxycycline</td> <td>Gentamicin, streptomycin</td> </tr> <tr> <td><em>Yersinia pestis</em></td> <td>Streptomycin, gentamicin</td> <td>Doxycycline, fluoroquinolone</td> </tr> <tr> <td><em>Bacillus anthracis</em> (inhalation)</td> <td>Ciprofloxacin, levofloxacin, doxycycline (usually with second agent)</td> <td>Other fluoroquinolones; beta-lactam, if susceptible; rifampin; clindamycin; chloramphenicol</td> </tr> <tr> <td>Enterobacteriaceae</td> <td>Third-generation cephalosporin, carbapenem<sup>◊</sup> (drug of choice if extended-spectrum beta-lactamase producer)</td> <td>Beta-lactam-beta-lactamase inhibitor<sup>§</sup>, fluoroquinolone</td> </tr> <tr> <td><em>Pseudomonas aeruginosa</em></td> <td>Antipseudomonal beta-lactam<sup>¥</sup> <strong>plus</strong> (ciprofloxacin or levofloxacin<sup>‡</sup> or aminoglycoside)</td> <td>Aminoglycoside <strong>plus</strong> (ciprofloxacin or levofloxacin<sup>‡</sup>)</td> </tr> <tr> <td><em>Burkholderia pseudomallei</em></td> <td>Carbapenem, ceftazidime</td> <td>Fluoroquinolone, TMP-SMX</td> </tr> <tr> <td><em>Acinetobacter</em> species</td> <td>Carbapenem</td> <td>Cephalosporin-aminoglycoside, ampicillin-sulbactam, colistin</td> </tr> <tr> <td colspan="3"><em>Staphylococcus aureus</em></td> </tr> <tr> <td class="indent1"> <ul> <li>Methicillin susceptible</li> </ul> </td> <td>Antistaphylococcal penicillin<sup>†</sup></td> <td>Cefazolin, clindamycin</td> </tr> <tr> <td class="indent1"> <ul> <li>Methicillin resistant</li> </ul> </td> <td>Vancomycin or linezolid</td> <td>TMP-SMX</td> </tr> <tr> <td><em>Bordetella pertussis</em></td> <td>Macrolide</td> <td>TMP-SMX</td> </tr> <tr> <td>Anaerobe (aspiration)</td> <td>Beta-lactam-beta-lactamase inhibitor<sup>§</sup>, clindamycin</td> <td>Carbapenem</td> </tr> <tr> <td>Influenza virus</td> <td>Refer to associated topic reviews**</td> <td> </td> </tr> <tr> <td><em>Mycobacterium tuberculosis</em></td> <td>Isoniazid plus rifampin plus ethambutol plus pyrazinamide</td> <td>Depends on susceptibility pattern; refer to associated topic reviews</td> </tr> <tr> <td><em>Coccidioides</em> species</td> <td>For uncomplicated infection in a normal host, no therapy generally recommended; for therapy, itraconazole, fluconazole</td> <td>Amphotericin B</td> </tr> <tr> <td>Histoplasmosis</td> <td>Itraconazole<sup>¶¶</sup></td> <td>Amphotericin B<sup>¶¶</sup></td> </tr> <tr> <td>Blastomycosis</td> <td>Itraconazole<sup>¶¶</sup></td> <td>Amphotericin B<sup>¶¶</sup></td> </tr> </tbody></table></div><div class="graphic_lgnd">Choices should be modified on the basis of susceptibility test results and advice from local specialists. Refer to local references for appropriate doses.<br/>
	Preferred agent may change over time due to changing resistance patterns and depends on many factors, including severity of illness. Refer to associated UpToDate topic reviews for updated and detailed treatment recommendations for each pathogen.</div><div class="graphic_footnotes">MIC: minimum inhibitory concentration; ATS: American Thoracic Society; CDC: United States Centers for Disease Control and Prevention; IDSA: Infectious Diseases Society of America; TMP-SMX: trimethoprim-sulfamethoxazole.<br/>
	
	* The 2 mcg/mL threshold is for nonmeningitis dosing. The threshold is lower for meningitis dosing.<br/>
	
	¶ Levofloxacin, moxifloxacin, gemifloxacin (not a first-line choice for penicillin-susceptible strains); ciprofloxacin is appropriate for <em>Legionella</em> and most gram-negative bacilli (including <em>H. influenzae</em>).<br/>
	
	Δ Azithromycin is more active in vitro than clarithromycin for <em>H. influenzae</em>.<br/>
	
	◊ Imipenem-cilastatin, meropenem, ertapenem.<br/>
	
	§ Piperacillin-tazobactam, ampicillin-sulbactam, ticarcillin-clavulanate (not available in the United States), or amoxicillin-clavulanate.<br/>
	
	¥ Ceftazidime, cefepime, aztreonam, imipenem, meropenem, or piperacillin (not available in the United States).<br/>
	
	‡ 750 mg daily.<br/>
	
	† Nafcillin, oxacillin, flucloxacillin.<br/>
	
	** Choice of antiviral regimen depends on type of influenza virus and expected resistance pattern. (Refer to the UpToDate topic on antiviral drugs for the treatment of influenza in adults.)<br/>
	
	¶¶ Preferred agent depends on severity of illness. Refer to associated UpToDate topic reviews for full discussions.</div><div class="graphic_reference">Adapted with permission from: Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thorac Society Consensus Guidelines on the Management of Community-acquired Pneumonia in Adults. Clin Infect Dis 2007; 44:S27. Copyright © 2007 University of Chicago Press.</div><div id="graphicVersion">Graphic 64816 Version 14.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
